Q-omics provides the consensus-scored CD200R1L profile across patient tissues and cancer cell-line models. CD200R1L expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CD200R1L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CD200R1L RNA expression shows 11,411 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where CD200R1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD200R1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD200R1L survival associations across molecular data types. CD200R1L RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD200R1L RNA expression–survival associations across cancer types. High CD200R1L expression shows unfavorable associations in STAD, COAD, LIHC, ACC and KIRP, but favorable associations in UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CD200R1L RNA expression.
This table summarizes CD200R1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CD200R1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD200R1L shows higher tumor expression in KIRC, LIHC, BLCA, LUSC, COAD and STAD. The KIRC box plot shows higher CD200R1L RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p < 0.001).
This table shows molecular features associated with CD200R1L in patient tissues and cancer cell lines. In patient samples, CD200R1L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD200R1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
